glp-1 dunn nc DietWorks Companion Weight Reduction with GLP-1 Agonists

Obesity Reviews : An Official Journal of the International Association for the Study of Obesity, 26 (8), e13929

[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity

But the differences in dosing, convenience, and potential results can make one a better fit than the other, depending on your needs

(2) in patients with a history of malignancy, particularly medullary thyroid carcinoma, the potential proliferative risks associated with GLP-1RAs must be weighed against their cardiovascular benefits

11,2325 EMPA-REG OUTCOME was a randomized, double-blind, placebo-controlled trial involving 7,020 patients with T2D and established cardiovascular disease (CVD)